<DOC>
	<DOCNO>NCT02806219</DOCNO>
	<brief_summary>This single center , open-label , Phase 1 bioequivalence ( BE ) study healthy subject design demonstrate bioequivalence single dose certolizumab pegol ( CZP ) 200mg injected mean prefilled syringe ( PFS , reference ) inject mean injection device ( e-Device , test ) .</brief_summary>
	<brief_title>Open-label , Bioequivalence Study Certolizumab Pegol 200 mg Solution Injected Either Prefilled Syringe ( Reference ) E-Device ( Test ) Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject male female 18 55 year age Screening . Subject good physical mental health status determine basis medical history general clinical examination . Subject evidence active inactive Tuberculosis ( TB ) . Female subject childbearing potential negative pregnancy test study entry use medically accept method contraception entire duration study 10 week final dose CZP . Female subject postmenopausal least 2 year serum follicle stimulate hormone ( FSH ) level &gt; 40mIU/mL Screening Visit , undergone hysterectomy , bilateral tubal ligation , and/or bilateral ovariectomy , congenital sterility consider childbearing potential . Subject receive live ( include attenuate ) vaccination immunoglobulin within 56 day precede CZP injection . Subject take drug ( include overthecounter medication ) within 56 day precede CZP injection ( exception note Section 7.8.1. ) . Subject know intolerant pegol . Subject previously receive CZP . Subject receive TNFÎ±inhibitors within 12 month biologic within 6 month randomization study . Subject active chronic/latent infection include TB , hepatitis C virus ( HCV ) , hepatitis B core antigen ( HBc ) , human immunodeficiency virus ( HIV ) . Subject symptomatic herpes zoster infection ( shingle ) within 6 month prior Screening . Subject chronic , serious , opportunistic recur infection condition within 6 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Human Volunteers</keyword>
</DOC>